Literature DB >> 16161422

[Studies on chemical constituents in the seeds of Nigella glandulifera].

Yu-ming Liu1, Jun-shan Yang, Qing-hua Liu.   

Abstract

OBJECTIVE: To investigate the chemical constituents in the seeds of Nigella glandulifera.
METHOD: The chemical constituents were isolated and repeatedly purified on silica gel column. They were identified and structurally elucidated by means of physio-chemical constants and spectral analysis. RESULT: Nine compounds were identified as nigellamose (I), alpha-hederin (II), 3-O-[beta-D-xylopyranosyl-(1-->3)-alpha-L-rhamnopyranosyl-(1-->2)-alpha-L-arabinpyranosyl]-hederagenin (III), sucrose (IV), stearic acid (V), 1-O-hexadecanolenin (VI), beta-sitosterol (VII), daucosterol (VIII) and p-hydroxybenzoic acid (IX).
CONCLUSION: I, II, III, VI, VIII and IX were obtained from the plant for the first time, and I is a new compound.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16161422

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  4 in total

1.  Flavonol glycosides, nigelflavonosides A-F from the whole plant of Nigella glandulifera (Ranunculaceae).

Authors:  Yi Zhang; Dandan Ge; Qiu Chen; Wei He; Lifeng Han; Hongyan Wei; Xiaoguang Jia; Tao Wang
Journal:  J Nat Med       Date:  2012-02-12       Impact factor: 2.343

2.  Cytotoxicity of two triterpenoids from Nigella glandulifera.

Authors:  Ze Tian; Yu-Ming Liu; Si-Bao Chen; Jun-Shan Yang; Pei-Gen Xiao; Liao Wang; Erxi Wu
Journal:  Molecules       Date:  2006-09-13       Impact factor: 4.411

3.  Chemical constituents from the seeds of Nigella glandulifera and their hypoglycemic activities.

Authors:  Qingqing Li; Jing Xu; Yiyu Chen; Wenli Xie; Gui Mei; Xueni Li; Yu Chen; Guangzhong Yang
Journal:  RSC Adv       Date:  2022-07-05       Impact factor: 4.036

4.  Evaluation on Anti-Inflammatory, Analgesic, Antitumor, and Antioxidant Potential of Total Saponins from Nigella glandulifera Seeds.

Authors:  Jun Zhao; Fang Xu; Hua Huang; Zhengyi Gu; Linlin Wang; Wei Tan; Jinhua He; Yan Chen; Chenyang Li
Journal:  Evid Based Complement Alternat Med       Date:  2013-02-20       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.